The presence of AKT1 mutation might have clinical implications based on the preclinical evidence that this mutant has been found resistant to AKT1/2 inhibitor, suggesting that pediatric AF patients probably would not benefit from this target treatment 20. This evidence concerns the gene AKT1 and atrial fibrillation.